Background: One of the difficuIties in assessing the contribution of tumour-related factors to cancer cachexia is measurement of the extent of disease where dissemination to multiple organ sites has occurred.
study the relative contributions of the extent of tumour (estimated by both tumour volume and increased levels of markers), diet and patient-related factors (appetite, metabolic hormones, immune activation, liver function and quality oflife) to weight loss were assessed in patients with colorectalliver metastases.
Introduction
Suggested mechanisms for cancer-related weight 10ss include hormone-induced changes in metabolisml, tumour-related immune activation with cytokine2.3 release, alteration in diet or appetite 4 and reduced gastrointestinal nutrient absorption5. Weight 10ss is usually associated with advanced cancer6 and one of the difficulties in assessing the contribution of tumour-related factors to weight 10ss is measurement of the extent of disease where dissemination to multiple organ sites has occurred.
Colorectal liver metastases are suited to the study of weight 10ss in advanced cancer because metastasis is predominantly to the liver7 and tumour volume can be measured by hepatic computed tomography (CT)8. In this liver .C. Fordy, C. Glover, D. C. Henderson et al. and Sickness Impact Profile (SIP)13 quality of life instruments, and a previously validated short dietary questionnaire 14 enquiring about food intake over tlle previous week.
All variables were expressed as median (interquartile range). Differences between variables were assessed either by Mann-Whitney U, paired Wilcoxon orFisher's tests, or lag rank test of Kaplan-Meier distributions, as indicated. Spearrnan's test was used for correlations and logistic regression analysis as described previouslyl5. The probability of error in the estimation of regression coefficients was determined using the one-sided Wald statisticl6.
The study was approved by the Chelsea and Westminster Hospital Ethics Cornmittee.
Forty patients (22 menj 14 with weight loss) were studied. The median survival oí patients in the weight loss group (157 (76-231) days) was significantly shorter than that oí patients in the stable weight group (403 (247 to more than 500) days) (P = 0'0004, log rank test).
Patients receiving chemotherapy or corticosteroids at the time of the study were excluded.
In accordance with previous evidence9 that patients who have lost more than 1 kg in body-weight during the previous month have a reduced survival, such patients were allocated to a 'weight loss' group and those who had not lost 1 kg during the previous month to a 'stable weight' group. Body mass index (BMI) was derived from the quotient of body-weight in kg by the square of patient height in metres. Blood was assayed for serum carcinoembryonic antigen (CEA), albumin, alkaline phosphatase, cortisol, growth hormone, insulin, thyroid-stimulating hormone (TSH), Creactive protein (CRP), soluble tumour necrosis factor receptor 1 (sTNFrl), interleukin (IL) 6, soluble IL-2 receptor a (sIL2ra) and neopterin, and plasma aspartate aminotransferase (AST), alanine aminotransferase (AL T) and bilirubin. All patients underwent blood sampling within 2 h of 11.00 hours following an overnight fasto Measurement of serum cortisol and insulin levels was by automated enzyme-linked immunosorbent assay (ELISA) (ES 700; Boehringer Mannheim, Lewes, UK). Serum growth hormone levels were measured using the ms immunoradiometric assay (OMNIA kit; ms, Boldon, Tyne and Wear, UK), serum TSH byautomated ELISA (ES 700; Boehringer Mannheim) and serum CEA by automated ELISA (Immulite; EURO DPC, Caernarfon, UK). Serum albumin, and plasma bilirubin, AST and AL T were measured using a Hitachi 7474 automated analyser (Boehringer Mannheim). CRP was measured by an automated immunoturbidimetric assay on an Olympus AU600 analyser (Olympus Diagnostic Systems, Eastleigh, UK), using reagents provided by the company and folIowing their recommended procedures. Serum CRP concentrations of up to 10 mg/l were considered to be within the normal range. Serum IL-6, sTNFrl, sIL2ra and neopterin were measured by ELISA lO using commercialIy available kits supplied by R and D Systems Europe, Abingdon, UK (IL6, sTNFrl, sIL2ra) and ICN Flow, Basingstoke, UK (neopterin). The sIL2ra assay coefficients of variation (supplied by the manufacturer) were less than 6.1 per cent (intra-assay) and less than 7.2 per cent (interassay); those for other immune product assays were within a similar range. Normal serum values (median (range)) reported by the suppliers were: IL-6, 1.6 (0,4-10'1) ng/l; sTNFrl, 1198 (749-1966) ng/l; sIL2ra, 1346 (676-2132) ng/l; and neopterin, less than 10 nmol/l. The upper value in each range was taken as the upper limit of normal.
Liver metastasis volume was measured from CT images taken within 14 days of blood sampling using a technique described previously8. Within the same time interval, alI patients completed the Hospital Anxiety and Depression (HAD) scalell, Rotterdam Symptom Checklist (RSC)12
Body-weight and body mass index There was no significant difference in either body-weight (weightloss,70.8 (6203-74.5) kg; stable weight, 734 (70.0-7900) kg;P = 00202,Mann-WhitneyUtest)orBMI(2501 (2105-27.5) versus 26.1 (23.1-2803); P = 0015, MannWhitney U test) at the time of study. A significant BMI reduction (P = 0.031, paired Wilcoxon test) occurred in the weight loss group between the time of study and 1 month later, but no significant BMI' reduction was detected within 3 months of the study in tJhe stable weight group (Fig. 1) . BMI was significantly reduced (P = 00035, Mann-Whitney U test) in the weight loss group compared with stable weight group at 1 month after study entry.
Quality of life
Significant increases between weight loss $d stable weight groups were detected for HAD scale depression (8-0 (3-0-900) versus 305 (200-605); P = 0001, Mann-Whitney U test), RSC physical symptom (17 (13-21) versus 11 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) ; P = 0'05) and SIP (158 (50-200) versus 66 (13-124); P = 0'02) scores. Significant difference$ in HAD scale anxiety and RSC psychosocial scores were not detected.
Appetite and diet
There were no significant differences (Fisher's test) in the distribution of answers to quality of life questions concerning lack of appetite (RSC que~tion 1), nausea (RSCI0), vomiting (RSCI4) or eating (SJ;Pe) between the Immune products There was a significant increase in CRP level in the weight loss compared with the stable weight group (61 (23-87) versus 10 (1-24) mg/l; P = 0'02, Mann-Whitney U test). There was also a significant increase in serum sIL2rIX level in the weightloss group (2174 (1039-3114) versus 1034 (667-1773) ng/l; P = 0,05, Mann-Whitney U test). Significant increases in serum IL-6, sTNFrl and neopterin levels between the groups were not detected (Mann-Whitney U test). The prevalence of patients with a raised serum irnmune product level above normal was significantly greater in the weight loss compared with the stable weight group for sIL2rIX (six of 11 versus tour of 23; P = 0'03, Fisher's test) and IL-6 (seven of 11 versus seven of 23; P = 0'05), but not for sTNFrl or neopterin. There were significant correlations between serum CRP and serum sIL2rIX (rs = 0'68, P < 0.0001) and IL-6 (rs = 046, P = 0'008) but not sTNFrl or neopterin levels. two groupS. Similarly, in the diet questionnaire, significant differences in dietary intake of protein, fat, sugar, starch, fibre, alcohol or in daily energy intake were not detected (Mann-Whitney U test) between weight loss and stable weight groups, whether corrected or uncorrected for body-weight. In addition, no significant difference in daily energy intake was identified in patients with a CRP of greater than 10 mg/l compared with those with a CRP of less than 10 mg/l (Mann-Whitney U test).
Metabolic hormones
There were no significant differences in serum levels of insulin, growth hormone, TSH or cortisol between the two groups (Mann-Whitney U tests).
Liver function tests
The serum alkaline phosphatase level was raised significantly more in the weight loss than the stable weight group (738 (237-1154) versus 280 (159-427) units/lj P = 0.002, Mann-Whitney U test). Significant differences in plasma bilirubin, AST and AL T, or serum alburnin were not detected (Mann-Whitney U tests). Logistic regression analysis of variables that were significantly different between the two groups selected serum CEA and sIL2rtl as the two independent variables on which weight loss most depended (Toble 1).
Tumour buIk
Liver metastasis volume was significantly greater in the weight loss group compared with the stable weight group (1179 (245-1517) versus 119 (23-523) mI; P = 0'003, Mann-Whitney U test). The serum CEA level was also significantly greater in the weight loss compared with stable weight group (606 (111-155) VernIS 65 (19-290) units; P = 0'01, Mann-Whitney U test). protein turnover and energy expenditureu. In the present study, the correlation of raised serum IL-6 and CRP levels with weight loss was consistent with involvement of the acute-phase protein response3 in the weight loss associated with colorectalliver metastases23. The absence of any association between serum sTNFrl or neopterin levels and weight loss suggests that tumour necrosis facto?3 and interferon activation24 of monocytes/macrophages did not have a role in weight loss, but this should be interpreted with caution as these effects mar have been apparent only at the local cellular level.
Release of sIL2rtl from the T lymphocyte surface into the serum is thought to occur after T lymphocyte upregulation25, and raised serum sIL2rtl levels have been reported previously in advanced colorectal cance?6. The finding that sIL2rtl was the immune product whose serum level was most closely related to weight loss suggests that T lymphocyte IL-2 receptor upregulation, in addition to the acute-phase protein response, mar influence weight loss. Reports that T lymphocytes from patients with advanced colorectal cancel are 'anergic' to in vitro challenge27, and that patients with colorectalliver metas tases have reduced cell-mediated immuniti8, appear inconsistent with these results. This association of T cell anergy, low serum IL-2 level and raised sIL2rtl level has been reported previously in both cancel and chronic inflammatory disorders29-31. The findings are compatible with factors associated with an inflammatory (innate) immune response to colorectal cancel activating32 a deficient cellular (acquired) response33. This combination ofT cell anergy associated with IL-2 receptor upregulation can be produced experimentally34 by alteration of the T cell receptor ligand using an antigenic peptide analogue on a functional antigen-presenting cell. Previous pharmacological strategies to reduce cytokine-related weight loss in cancel have focused on agents that reduce monocyte-related cytokines in the acute-phase protein response21,35. Agents that influence T lymphocyte IL-2 receptor release might also be beneficial.
Both tumour volume and the tumour marker serum CEA level correlated with weight loss, and serum CEA was the strongest predictor of weight loss in the regression analysis. This suggests either that the circulating levels of immune products measured did not accurately represent the immune products which influenced metabolism at the cellular leve136 or that tumour-related products also influenced weight loss by non-immunological mechanisms35.
No significant differences in serum levels of hormones that influence metabolism were detected. It is possible that the effects of these hormones altered without a change in serum levels, but the present findings did not support a Discussion Although loss of more than 1 kg body-weight during the previous month 9 was associated with a tenfold increase in median liver metastasis volume, the difference in bodyweight between the weight loss and stable weight groups at the time of study was small (median 2.6 kg). The weight difference between the groups might be reduced because patients in the stable weight group mar also have lost some weight without fulfilling the criterion required for the weight loss group (1oss of 1 kg in the preceding month). However, the finding that there was no weight loss in the stable weight group during the 3 months after the study makes it unlikely that these patients had lost weight during the preceding month. The extent of weight loss in the weight loss group did not reach the level of 11 per cent of premorbid weight, which has been reported for pancreatic cancer17, until 3 months after the study by which time most patients had reached the terminal stage of disease. Thus weight loss from colorectal liver metastases was associated with a large tumour volume, and with an equivalent weight loss to that in pancreatic Cáncer being reached only by the terminal stage of the natural history.
Since the study was undertaken before the greatest fall in BMI (0-1 month after the study), it is likely that the abnormalities detected were a consequence of the disease rather than the weight loss. The food frequency questionnaire is a well established technique for identifying current food intake. The accuracy of dietary questionnaires mar be limited by patient recall when questioned about diet during the previous month, but prospective data collection can influence eating behaviour and methods based on weighed dietary intake are too arduous for this group of patients.
Although the deterioration in depression and physical symptoms that is associated with larger liver metastases18 was identified in patients who lost weight, this deterioration was not associated with a significant reduction in appetite or food and energy intake. Wigmore et aP 7 reported that energy intake was reduced by 29 per cent in patients with pancreatic cancer in whom an acute-phase protein response, defined by a serum CRP level of greater than 10 mg/l, was identified. In the present study of patients with colorectal liver metastases, significant decreases in food or energy intake did not correlate with a raised CRP level. This mar be one explanation for the greater weight loss reported with pancreatic cancer compared with colorectal cancer.
Monocyte/macrophage release19 of the cytokine IL-6 stimulates hepatocyte CRP productionZO.Zl with activation of an acute-phase protein response which influences role for honnone'-related metabolic changes in the weight loss produced by colorectal liver metastases. The lack of an association of plasma AST or AL T with weight loss suggests that reduced liver function from liver metastasisrelated hepatocyte destruction was unlikely to explain the weight loss. This is consistent with the observation8 that hepatic parenchymal volume is not reduced in patients with colorectalliver metastases.
In summary, significant weight loss from colorectalliver metastases required a large tumour volume. This weight loss was not explained by changes in diet, quality of life or honnones, but activation of the innate and incomplete activation of the acquired immune systems were likely to be involved. Additional non-immune-mediated tumourrelated factors may also be important.
